ABB India wins order to automate Reliance Life Sciences’ Nashik Unit
In a recent announcement on August 21, ABB India has clinched a significant contract from Reliance Life Sciences (RLS) to implement state-of-the-art automation and control solutions at their newly planned biosimilars and plasma protein manufacturing complexes in Nashik, Maharashtra.
The project’s scope entails the comprehensive automation of production procedures utilizing ABB’s cutting-edge distributed control system (DCS) known as System 800xA. This advanced solution encompasses Remote I/O systems, Batch Recipe Management, and seamless MES integration. With the integration of ABB’s innovative technology, RLS is set to revamp its manufacturing processes, adhere to stringent regulatory benchmarks, and elevate its product quality standards.
The deployment of ABB’s DCS on the latest Windows platform provides an array of benefits for RLS. This sophisticated system promises to reduce overall ownership costs while serving as a unified platform for real-time monitoring of different plant segments and optimization of maintenance protocols. This technology not only facilitates streamlined data communication but also minimizes wiring complexities, optimizes hardware usage, and expedites project completion.
Situated on a sprawling 160-acre property, the Nashik facility is poised to house manufacturing units dedicated to various products including plasma proteins, biopharmaceuticals, oncology medications, and vaccines. Given the intricacies of large-scale biotech manufacturing and the necessity of strict regulatory compliance, ABB’s System 800xA emerges as a crucial tool to mitigate production errors, assure consistent product quality, and enable smooth operator interaction and batch management.
G Balaji, Senior Vice-President and Head of Energy Industries at ABB India, expressed his excitement about the collaboration, stating, “Our partnership with Reliance Life Sciences on this pivotal project is a source of pride for us. It will reinforce our foothold in the pharmaceutical and life sciences domain, where we envision remarkable potential for expansion and innovation.”
RLS President KV Subramaniam emphasized the pivotal role of automation technologies in manufacturing processes, stating, “Our collaboration with ABB isn’t just a part of our continuous improvement journey but also a substantial leap towards virtualization and process control enhancement.”
In addition to the DCS integration, RLS stands to gain from ABB’s modular remote I/O solution, introducing a user-friendly plug-and-play concept to the automation landscape. This solution guarantees swifter commissioning, smoother process assimilation, and the flexibility to scale plant capacity in the future.
With the expansion of its manufacturing facilities, Reliance Life Sciences remains steadfast in its mission to deliver top-notch biosimilars at an affordable cost, thereby positively impacting healthcare accessibility.
About ABB India:
ABB India Ltd, previously recognized as ABB Ltd, stands as a premier global engineering enterprise, dedicated to enabling customers in harnessing electrical power with maximum efficiency and elevating industrial output. The corporation boasts a substantial manufacturing infrastructure and an expansive nationwide network for marketing and service provisions.
For more of the Latest News, Click Here